Market Competition and Healthcare Policy

Expert Panelists: David C. Grabowski, PhD (Harvard Medical School); R. Tamara Konetzka, PhD (University of Chicago); Anne Deutsch, RN, PhD (RTI International)

With organ shortages claiming thousands of lives annually, this session explores whether carefully designed market mechanisms can increase donation rates while maintaining ethical standards and preventing exploitation.

MIT's Amy Finkelstein and Stanford's Liran Einav present their provocative vision for replacing America's fragmented insurance system with universal, automatic coverage designed for security, equity, and simplicity.

With commercial healthcare prices remaining stubbornly opaque and variable, this session will model how price transparency policies offer employers a powerful tool to control rising healthcare costs and empower more informed purchasing decisions.

Brian Miller for Social Science Research Network

Andrew Anderson, Mark Meiselbach and Kali Thomas for Health Affairs Forefront

Melinda B. Buntin, and Angela Liu for JAMA Health Forum

Michael Darden for JAMA Network Open

Haiyang Yang for Journal of the Association for Consumer Research

Yashaswini Singh, and Daniel Polsky for Health Affairs

Antonio Trujillo, Mariana Socal and Gerard Anderson for Journal of Economic Analysis

Mark Meiselbach for Health Affairs Forefront

Katherine E M Miller, Ravi Gupta, and Daniel Polsky for Health Affairs Scholar

The panel, moderated by Michael Darden, Assistant Professor at Johns Hopkins University's Carey School of Business, included Henry Waxman, Former U.S. Congressman and Chairman at Waxman Strategies; Mitch Zeller, J.D., Former Director of the Center for Tobacco Products, FDA; Barbara Schillo, Ph.D., Chief Research Officer, Truth Initiative; and David Levy, Ph.D., Professor of Oncology, Georgetown University.

Melinda Buntin for JAMA Health Forum

Yang Wang, Jianhui Xu, and Gerard Anderson for JAMA Network Open

Jeromie Ballreich and Mariana P. Socal for JAMA Pediatrics

Jeffrey Drope for Economics for Health

Emilia Simeonova for Management Science

Journal of General Internal Medicine

Ge Bai for Health Affairs Forefront

Tej D. Azad, Rachel J. Wu, Kelly E. Anderson, Michael Darden & Amit Jain for Osteoporosis International

Joseph F. Levy, Mariana P. Socal, and Jeromie M. Ballreich for JAMA Health Forum

Hossein Zare and Gerard Anderon for the Journal of Healthcare Management

Melinda Buntin for Health Affairs Scholar

Ge Bai for Health Affairs

Tinglong Dai for the National Bureau of Asian Research

Ge Bai for JAMA Health Forum

Eric Slade and Laura Samuel for Medical Care Research and Review

HBHI is pleased to announce our six pilot grant awardees for our 2025 cohort.

Michael Keane for Institute for Fiscal Studies

Mariana P. Socal and Antonio J. Trujillo for Expert Opinion on Biological Therapy

Jeffery Drope for the Task Force on Fiscal Policy for Health

Get to know Nicholas Tilipman, Ph.D., a new assistant professor at the Johns Hopkins Carey School of Business and member of HBHI's core faculty. His work explores the effects of competition and regulation on the behavior of employers, insurers, and providers.

You’re invited to access this exclusive FMG Leading/Fierce Healthcare panel discussion featuring HBHI Director Dan Polsky to learn more.

The panel, moderated by Andrew Anderson, PhD, Assistant Professor at Johns Hopkins University, included Andy Higgins, VP of Product Development at Clever Care; Sachin Jain, CEO of SCAN Group and SCAN Health Plan; Mark Meiselbach, Assistant Professor at Johns Hopkins University; and Casey Schwarz, Senior Counsel for Federal Policy.

Ravi Gupta and G Caleb Alexander for Health Affairs Scholar

Melinda Buntin in The New England Journal of Medicine

Mariana P. Socal and Ge Bai in JAMA Network.

Lindsay Thompson in Frontiers in Public Health

Haiyang Yang in Handbook of Qualitative Research Methods in Marketing: Second Edition

Alene Kennedy-Hendricks in Environmental Health Insights

Jason Brian Gibbons, Manuel Hermosilla and Antonio Trujillo in Health Services Research

Angela Liu Kelly E. Anderson, Joseph Levy, Daniel Polsky, and Gerard Anderson in JAMA Health Forum

Expert Panelists: Chapin White, Director of Health Analysis, CBO; Meena Seshamani, MD, PhD, Deputy Administrator and Director, CMS; Tom Buchmueller, Deputy Assistant Secretary, ASPE, HHS and Professor, Michigan Ross; and Marta Wosińska, PhD, Senior Fellow, Brookings

Featuring Former Representative Henry Waxman; Mitch Zeller, J.D., Former Director of the Center for Tobacco Products, FDA; Barbara Schillo, Ph.D., Chief Research Officer, Truth Initiative; David Levy, Ph.D., Professor of Oncology, Georgetown University

Gene and RNA therapies are promising treatments for many rare diseases. Pediatric populations that could benefit from these drugs are overrepresented among state Medicaid programs.

Over 70% of Medicaid beneficiaries are enrolled in Medicaid managed care (MMC). MMC provider networks therefore represent a critical determinant of access to the Medicaid program

The rise in prevalence of high deductible health plans (HDHPs) in the United States may raise concerns for high-need...

A substantial proportion of individuals with depression in the United States do not receive treatment.

To examine the relationship between growth in Medicare Advantage (MA) enrollment and changes in finances at skilled nursing facilities (SNFs).

Most policy analysis methods and approaches are applied retrospectively.

Getting hospitals to participate in value-based payment reform voluntarily is a challenge.

With a variety of candidates vying for the Republican presidential nomination and President Joe Biden seeking re-election in the wake of the COVID-19 pandemic, health policy will remain a central issue for voters in the 2024 election.

Insurance exists to protect enrollees against their financial exposure to catastrophically high-cost low-probability events. Indeed, health insurance began as sickness funds, where workers made weekly contributions to a fund that would temporarily provide a reduced wage to those too ill to work.

Comparison of prior authorization across insurers: cross-sectional evidence from Medicare Advantage

The goal of this webinar is to discuss the ecosystem of markets for blood and blood components in the US, the structure of the market ecosystem, the challenges faced, and the steps underway to address the challenges and ensure a stable supply of blood and blood components for patients in need.

Michael's upcoming article in the Journal of Risk and Uncertainty

Melinda sat down to discuss the report on 2022 health care spending from the CMS Office of the Actuary.

"Happy to become a new member of @MHCCMD Payment Model Work Group" Read more on her announcement here.

What is the association of recreational and medical cannabis legalization with opioid prescriptions and fatal overdoses in the US?

To validate imputation methods used to infer plan-level deductibles and determine which enrollees are in high-deductible health plans (HDHPs) in administrative claims datasets

Biosimilar uptake in the United States is limited. It has not been comprehensively studied in Medicare Advantage (MA).

HBHI is pleased to announce our five pilot grant awardees for our 2024 cohort.

Are Medicare Advantage plans’ provider networks associated with beneficiaries’ receiving care from primary care clinicians with lower rates of avoidable hospital stays?

This article is the latest in the Health Affairs Forefront series, Provider Prices in the Commercial Sector, featuring analysis and discussion of physician, hospital, and other health care provider prices in the private-sector markets and their contribution to overall spending therein.

As of 2020, 70% of Medicaid beneficiaries (57 million) were insured through Medicaid managed care (MMC), in which a private insurer covers a beneficiary’s medical care in exchange for fixed payments from state Medicaid agencies.1 A key role of MMC insurers is to negotiate prices with hospitals. MMC prices have important implications for government health expenditures and access to care for Medicaid beneficiaries. However, little is known about MMC prices.2 We used hospitals’ self-disclosed pricing information to characterize MMC hospital prices.

The Hopkins Business of Health Initiative (HBHI) had its Washington DC debut at a September 22 Open House at Johns Hopkins University’s (JHU) beautifully renovated 555 Pennsylvania Avenue building. The location was a testament to JHU’s commitment to engaging in debates of national and global policy. The event introduced HBHI and JHU to the community of national leaders working specifically on health policy in the nation’s capital, welcoming them to HBHI’s new “spiritual home.”

We study the effects of changing Medicaid reimbursement rates for primary care services on behavioral health outcomes—defined here as mental illness and substance use disorders.

There is much debate about the effects of pharmaceutical direct to consumer advertising (DTCA) on health care use. In this paper, we inform this debate by examining the effects of DTCA on office visits, as well as treatment courses resulting from those visits, for five common chronic conditions (hypertension, hyperlipidemia, diabetes, depression, and osteoporosis). In particular, we examine whether office visits result in use of drug therapy and/or continued office visits over time.

Despite growth in private equity (PE) acquisitions of physician practices in the US, little is known about how changes in ownership influence workforce composition. Using clinician-level data linked to practice acquisition information, we estimated changes in clinician workforce composition in PE-acquired practice sites relative to non-PE-acquired independent practice sites for dermatology, ophthalmology, and gastroenterology specialties.

Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.

In this cross-sectional analysis of the top 1000 generics in Colorado’s all-payer claims database in 2019, 45 high-cost generics that had lower-cost therapeutic alternatives of same clinical value were identified. Overall, high-cost generics were 15.6 times more expensive than their therapeutic alternatives (median values); if the lower-cost alternatives had been used, total spending would have been reduced by 88.3%.

Around 150 million Americans rely on employers for access to health care. Can the companies who employ them help foster an affordable system that improves our health and doesn't drive us crazy in the process?

Medicare beneficiaries frequently select suboptimal Medicare Advantage plan products or elect traditional fee-for-service Medicare due to choice paralysis, cognitive impairments, and consumer health insurance illiteracy. Medicare Advantage Chronic Condition Special Needs Plans (C-SNPs) offer an opportunity to tie disease to both plan design and marketing, simplifying consumer choice architecture.

Mario Macis, PhD of Carey Business School and member of HBHI’s Leadership Committee won a 2020 HBHI pilot grant on “Social Support for Markets in Health and Healthcare: Insights from the COVID-19 Pandemic.” His efforts produced a working paper which was disseminated in April 2022 by the National Bureau of Economic Research (NBER) as well as two research networks in Germany.

Price surges often generate social disapproval and requests for regulation and price controls, but these interventions may cause inefficiencies and shortages. To study how individuals perceive and reason about sudden price increases for different products under different policy regimes, we conduct a survey experiment with Canadian and U.S. residents.

Facing unprecedented uncertainty and drastic trade-offs between public health and other forms of human well-being, policy makers during the Covid-19 pandemic have sought the guidance of epidemiologists and economists.

Medicare Advantage and the Maryland all-payer model

Since the beginning of the COVID-19 pandemic in 2020 policymakers have consulted epidemiologists and economists to determine the best course of action.